Skip to main navigation Skip to search Skip to main content

Nanovehicles for co-delivery of anticancer agents

  • Mahdi Zeinali
  • , Soheil Abbaspour-Ravasjani
  • , Marjan Ghorbani
  • , Afshin Babazadeh
  • , Tannaz Soltanfam
  • , Ana Cláudia Santos
  • , Hamed Hamishehkar
  • , Michael R. Hamblin

Research output: Contribution to journalReview articlepeer-review

109 Citations (Scopus)

Abstract

Using nanovehicles for co-delivery of two or more anticancer agents shows benefits including: synergistic effects, promoting apoptosis pathways, reduction of toxicity and side effects, and overcoming multidrug resistance.

Original languageEnglish
Pages (from-to)1416-1430
Number of pages15
JournalDrug Discovery Today
Volume25
Issue number8
DOIs
Publication statusPublished - Aug 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Nanovehicles for co-delivery of anticancer agents'. Together they form a unique fingerprint.

Cite this